John Murphy III CV
Experience

Chief Executive Officer
Association for Accessible Medicines
Oct 2024 - Present · 9 mos
Washington, District of Columbia, United States · On-site

John Murphy is the President and CEO of the Association of Accessible Medicines (AAM), the preeminent global trade association representing the prescription generics and biosimilars industry. Under his leadership, AAM is dedicated to enhancing access to safe, high-quality, and affordable medication for all patients in need.

The accessible medicines sector plays a critical role in the U.S. healthcare landscape, with AAM members producing an impressive 90% of all prescription medications dispensed in the country while accounting for just 13% of total drug spending. Over the past decade, these members have collectively contributed to savings of more than $3 trillion for patients and the broader healthcare system in the United States.

Mr. Murphy is at the forefront of AAM's efforts to foster a sustainable and resilient supply chain for generics and biosimilars, while continuously striving to broaden the range of affordable medication options available globally from AAM members. An acknowledged authority in drug pricing policy, reimbursement strategies, and FDA regulations, he frequently shares his insights through speaking engagements and publications focusing on patient access, drug pricing, and overarching healthcare policy issues.

John Murphy is the President and CEO of the Association of Accessible Medicines (AAM), the preeminent global trade association representing the prescription generics and biosimilars industry. Under his leadership, AAM is dedicated to enhancing access to safe, high-quality, and affordable medication for all patients in need. The accessible medicines sector plays a critical role in the U.S. healthcare landscape, with AAM members producing an impressive 90% of all prescription medications dispensed in the country while accounting for just 13% of total drug spending. Over the past decade, these members have collectively contributed to savings of more than $3 trillion for patients and the broader healthcare system in the United States. Mr. Murphy is at the forefront of AAM's efforts to foster a sustainable and resilient supply chain for generics and biosimilars, while continuously striving to broaden the range of affordable medication options available globally from AAM members. An acknowledged authority in drug pricing policy, reimbursement strategies, and FDA regulations, he frequently shares his insights through speaking engagements and publications focusing on patient access, drug pricing, and overarching healthcare policy issues.

Editorial Board Member
Life Science Compliance Update
Jan 2015 - Oct 2024 · 9 yrs 10 mos

Biotechnology Innovation Organization
Chief Policy Officer & Healthcare Counsel
Oct 2021 - May 2024 · 2 yrs 8 mos
Washington, District of Columbia, United States

Career Highlights

- Strategic Legal Leadership: Directed comprehensive legal strategies as Chief Policy Officer & Senior Counsel at BIO, guiding policy, legal, and international advocacy initiatives on behalf of 1,000+ biotech member companies. Provided expert counsel to BIO's leadership and board and led the organizational strategy on regulatory and policy program advocacy within government agencies, Congress, and international entities.
- Access and Reimbursement Expert: Crafted and executed transformative legislative and regulatory proposals, successfully navigating complex regulatory landscapes to construct novel CMS coverage and state access programs for innovative medicines. Litigated against multiple misguided government proposals and anti-industry ballot initiatives, safeguarding industry interests.
- Government Affairs Oversight: Managed multifaceted FDA, CMS, USDA, and government affairs portfolios through orchestration of legal and legislative strategies across agencies and within Congress. Provided expert guidance on healthcare reform, agricultural and climate innovation, and broad biotech-related public health matters.
- Global Policy Advocacy: Led international advocacy campaigns at the World Trade Organization and United Nations, championing global intellectual property rights for biotechnology products. Extensive experience in shaping global policy and navigating multi-lateral organizations.

Skills: Team Management · Drug Development · Board of Directors · Regulatory Compliance · Environmental Biotechnology · Governmental Affairs · Legal Compliance · Litigation · Corporate Governance · Biofuels

Vice President and Deputy General Counsel
Jan 2020 - Nov 2021 · 1 yr 11 mos
Washington D.C. Metro Area
Skills: Team Management · Drug Development · Regulatory Compliance · Governmental Affairs · Litigation · Corporate Governance

Deputy General Counsel
Dec 2016 - Jan 2020 · 3 yrs 2 mos
Washington D.C. Metro Area
Skills: Drug Development · Regulatory Compliance · Environmental Biotechnology · Governmental Affairs · Litigation

Assistant General Counsel
PhRMA
Aug 2013 - Dec 2016 · 3 yrs 5 mos
Washington D.C. Metro Area
Skills: Drug Development · Regulatory Compliance · Governmental Affairs · Legal Compliance · Litigation · Corporate Governance

Senior Director, State Government Relations, Health Policy
Biotechnology Industry Organization
Feb 2010 - Aug 2013 · 3 yrs 7 mos

- Responsible for developing and managing positions on healthcare issues impacting biotech therapy access and development throughout the country.
- Manage all state-level advocacy for healthcare issues on behalf of the organization and its members.

Skills: Environmental Biotechnology

Associate
Hogan & Hartson LLP
Sep 2007 - Mar 2010 · 2 yrs 7 mos

- Primary focus on pharmaceutical and medical device company compliance and government investigations.
- Secondary focus on federal health policy and information privacy issues.

Skills: Drug Development · Legal Compliance · Corporate Governance

Senior Consultant
McBee Associates
Jul 2002 - May 2004 · 1 yr 11 mos

- Responsible for management and improvement of non-profit hospital billing and finance functions.